Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models
Aurora A kinase and MEK inhibitors induce different, and potentially complementary, effects on the cell cycle of malignant cells, suggesting a rational basis for utilizing these agents in combination. In this work, the combination of an Aurora A kinase and MEK inhibitor was evaluated in pre-clinica...
Main Authors: | S. Lindsey eDavis, Kelli M. Robertson, Todd M. Pitts, John J. Tentler, Erica L. Bradshaw-Pierce, Peter J. Klauck, Stacey M. Bagby, Stephanie L. Hyatt, Heather M. Selby, Anna eSpreafico, Jeffrey A Ecsedy, John J. Arcaroli, Wells A. Messersmith, Aik Choon eTan, S. Gail eEckhardt |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2015-06-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fphar.2015.00120/full |
Similar Items
-
Association of the Epithelial-to-Mesenchymal Transition (EMT) Phenotype with Responsiveness to the p21-Activated Kinase Inhibitor, PF-3758309, in Colon Cancer Models
by: Todd M Pitts, et al.
Published: (2013-03-01) -
Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer.
by: Todd M Pitts, et al.
Published: (2014-01-01) -
Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer
by: Peter J. Klauck, et al.
Published: (2018-02-01) -
Tumor p-glycoprotein correlates with efficacy of PF-3758309 in in vitro and in vivo models of colorectal cancer.
by: Erica Lynn Bradshaw-Pierce, et al.
Published: (2013-03-01) -
Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers
by: S. Lindsey Davis, et al.
Published: (2014-05-01)